Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
A systemic Vasculitis is found in 5 to 10% of HCV infected patients with mixed
cryoglobulinemia (MC). It mainly involves the skin, peripheral nerve and the kidney and may
be life threatening. Twenty to 30% of HCV-MC Vasculitis patients are resistant to
conventional therapy (i.e. antiviral therapy and/or immunosuppressors) and still have an
active disease. Thus, new therapeutic approaches are necessary in such patients. We recently
described a regulatory T cell (Treg) deficiency in HCV-related Vasculitis patients.
Immunomodulatory effects of interleukin-2 (IL-2) are well established, notably the
preferential expansion of Treg able to suppress inflammatory responses mediated by CD4+ and
CD8+ T cells.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis